TY - JOUR
T1 - Risk of second primary malignancy in patients with primary myelofibrosis
T2 - a SEER database study
AU - Joshi, Utsav
AU - Bhattarai, Adheesh
AU - Gaire, Suman
AU - Gill, Simrat
AU - Agrawal, Vishakha
AU - Yadav, Sumeet Kumar
AU - Low, Soon Khai
AU - Dhakal, Prajwal
AU - Bhatt, Vijaya Raj
AU - Kouides, Peter A.
N1 - Publisher Copyright:
© 2022 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2022
Y1 - 2022
N2 - Prior studies report a greater incidence of second primary malignancy (SPM) among patients with myeloproliferative neoplasms, although the true risk in primary myelofibrosis (PMF) has not been elucidated. We utilized the Surveillance, Epidemiology, and End Results database to evaluate the risk of SPM in PMF patients and analyzed the effects of sociodemographic factors on the risk of SPM. Out of 5273 patients, 385 patients (7.30%) developed SPM. SPM occurred at SIR of 1.95 (95% CI 1.76–2.15) and AER of 149.01 per 10,000 population. A significantly higher incidence of melanoma (SIR 1.76, 95% CI 1.01–2.86), lymphoma (SIR 3.38, 95% CI 2.28–4.83), and leukemia (SIR 27.19, 95% CI 23.09-31.81) was observed. The risk was significantly higher in patients ≤60 years, males, chemotherapy recipients, within 5 years of PMF diagnosis, and for PMF diagnosed after 2009.
AB - Prior studies report a greater incidence of second primary malignancy (SPM) among patients with myeloproliferative neoplasms, although the true risk in primary myelofibrosis (PMF) has not been elucidated. We utilized the Surveillance, Epidemiology, and End Results database to evaluate the risk of SPM in PMF patients and analyzed the effects of sociodemographic factors on the risk of SPM. Out of 5273 patients, 385 patients (7.30%) developed SPM. SPM occurred at SIR of 1.95 (95% CI 1.76–2.15) and AER of 149.01 per 10,000 population. A significantly higher incidence of melanoma (SIR 1.76, 95% CI 1.01–2.86), lymphoma (SIR 3.38, 95% CI 2.28–4.83), and leukemia (SIR 27.19, 95% CI 23.09-31.81) was observed. The risk was significantly higher in patients ≤60 years, males, chemotherapy recipients, within 5 years of PMF diagnosis, and for PMF diagnosed after 2009.
KW - Primary myelofibrosis
KW - incidence
KW - leukemia
KW - melanoma
KW - second primary malignancy
UR - http://www.scopus.com/inward/record.url?scp=85139174591&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85139174591&partnerID=8YFLogxK
U2 - 10.1080/10428194.2022.2123227
DO - 10.1080/10428194.2022.2123227
M3 - Article
C2 - 36120968
AN - SCOPUS:85139174591
SN - 1042-8194
VL - 63
SP - 3456
EP - 3461
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 14
ER -